TW200732308A - Substituted 4-aminoquinazoline derivatives, preparation thereof and therapeutic application thereof - Google Patents

Substituted 4-aminoquinazoline derivatives, preparation thereof and therapeutic application thereof

Info

Publication number
TW200732308A
TW200732308A TW095137552A TW95137552A TW200732308A TW 200732308 A TW200732308 A TW 200732308A TW 095137552 A TW095137552 A TW 095137552A TW 95137552 A TW95137552 A TW 95137552A TW 200732308 A TW200732308 A TW 200732308A
Authority
TW
Taiwan
Prior art keywords
alkylene
alkyl
aryl
optionally substituted
nrarb
Prior art date
Application number
TW095137552A
Other languages
English (en)
Chinese (zh)
Inventor
Jean Michel Augereau
Gilles Courtemanche
Pierre Despeyroux
Michel Geslin
Anne Thomas
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36645639&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TW200732308(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of TW200732308A publication Critical patent/TW200732308A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
TW095137552A 2005-10-12 2006-10-12 Substituted 4-aminoquinazoline derivatives, preparation thereof and therapeutic application thereof TW200732308A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0510409A FR2891829A1 (fr) 2005-10-12 2005-10-12 Derives de la 4-amino-quinazoline, leur preparation et leur application en therapeutique

Publications (1)

Publication Number Publication Date
TW200732308A true TW200732308A (en) 2007-09-01

Family

ID=36645639

Family Applications (1)

Application Number Title Priority Date Filing Date
TW095137552A TW200732308A (en) 2005-10-12 2006-10-12 Substituted 4-aminoquinazoline derivatives, preparation thereof and therapeutic application thereof

Country Status (5)

Country Link
AR (1) AR056688A1 (fr)
FR (1) FR2891829A1 (fr)
TW (1) TW200732308A (fr)
UY (1) UY29857A1 (fr)
WO (1) WO2007042669A2 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2061767B1 (fr) 2006-08-08 2014-12-17 Sanofi Imidazolidin-2,4-diones arylaminoaryl-alkyl-substituées, procédé de fabrication, médicaments les contenant et leur utilisation
BRPI0912988A2 (pt) 2008-05-22 2019-09-24 Allergan Inc compostos bicíclicos tendo atividade no receptor cxcr4.
UY31968A (es) 2008-07-09 2010-01-29 Sanofi Aventis Nuevos derivados heterocíclicos, sus procesos para su preparación, y sus usos terapéuticos
WO2010068601A1 (fr) 2008-12-08 2010-06-17 Sanofi-Aventis Hydrate de fluoroglycoside hétéroaromatique cristallin, ses procédés de fabrication, ses procédés d'utilisation et compositions pharmaceutiques le contenant
KR20120060207A (ko) 2009-08-26 2012-06-11 사노피 신규한 결정성 헤테로방향족 플루오로글리코시드 수화물, 이들 화합물을 포함하는 약제 및 이들의 용도
EP2683704B1 (fr) 2011-03-08 2014-12-17 Sanofi Dérivés oxathiazine ramifiés, procédé pour leur préparation, utilisation en tant que médicament, agents pharmaceutiques contenant ces dérivés et leur utilisation
WO2012120056A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés oxathiazine tétra-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683699B1 (fr) 2011-03-08 2015-06-24 Sanofi Dérivés oxathiazine di- et tri-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation
EP2766349B1 (fr) 2011-03-08 2016-06-01 Sanofi Dérivés d'oxathiazine substitués par des carbocycles ou des hétérocycles, leur procédé de préparation, médicaments contenant ces composés et leur utilisation
HK1246593A1 (zh) * 2015-06-04 2018-09-14 Kura Oncology, Inc. 用於抑制menin蛋白与mll蛋白的相互作用的方法及组合物
PH12018501955B1 (en) 2016-03-16 2024-01-24 Kura Oncology Inc Bridged bicyclic inhibitors of menin-mll and methods of use
PL3429591T3 (pl) 2016-03-16 2023-07-17 Kura Oncology, Inc. Podstawione pochodne tieno[2,3-d]pirymidyny jako inhibitory meniny-mll i metody ich zastosowania
WO2018175746A1 (fr) 2017-03-24 2018-09-27 Kura Oncology, Inc. Méthodes de traitement d'hémopathies malignes et du sarcome d'ewing
WO2018226976A1 (fr) 2017-06-08 2018-12-13 Kura Oncology, Inc. Procédés et compositions d'inhibition de l'interaction de la ménine avec les protéines mll
EP3684361A4 (fr) 2017-09-20 2021-09-08 Kura Oncology, Inc. Inhibiteurs substitués de ménine-mll et méthodes d'utilisation
EP4444313A4 (fr) * 2021-12-09 2025-12-31 Bala Therapeutics Inc Inhibiteurs de l'interaction ménine-mll

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0126087A1 (fr) * 1982-09-24 1984-11-28 Beecham Group Plc Derives d'amino-azabicycloalkyle utilises en tant qu'antagonistes de la dopamine
GB2295387A (en) * 1994-11-23 1996-05-29 Glaxo Inc Quinazoline antagonists of alpha 1c adrenergic receptors
EP1432693A2 (fr) * 2001-10-01 2004-06-30 Taisho Pharmaceutical Co. Ltd. Antagonistes du recepteur de la mch
MXPA04012440A (es) * 2002-06-12 2005-04-28 Abbott Lab Antagonistas de receptor de hormona concentradora de melanina.
AU2003287880A1 (en) * 2002-12-11 2004-06-30 7Tm Pharma A/S Cyclic quinoline compounds for use in mch receptor related disorders
CL2004000409A1 (es) * 2003-03-03 2005-01-07 Vertex Pharma Compuestos derivados de 2-(cilo sustituido)-1-(amino u oxi sustituido)-quinazolina, inhibidores de canales ionicos de sodio y calcio dependientes de voltaje; composicion farmaceutica; y uso del compuesto en el tratamiento de dolor agudo, cronico, neu
KR20060079121A (ko) * 2004-12-31 2006-07-05 에스케이케미칼주식회사 당뇨 및 비만 치료예방에 유효한 퀴나졸린 유도체

Also Published As

Publication number Publication date
WO2007042669A2 (fr) 2007-04-19
FR2891829A1 (fr) 2007-04-13
UY29857A1 (es) 2007-05-31
AR056688A1 (es) 2007-10-17
WO2007042669A3 (fr) 2007-05-31

Similar Documents

Publication Publication Date Title
TW200732308A (en) Substituted 4-aminoquinazoline derivatives, preparation thereof and therapeutic application thereof
MX2010003495A (es) Derivados de quinazolinadiona, su preparacion y sus aplicaciones terapeuticas.
TW200722079A (en) Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
UA95976C2 (en) 2-ARYL-6-PHENYLIMIDAZO[1,2-b]PYRIDINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF
TW200609204A (en) Sulfonamide derivatives, preparation thereof and therapeutic application thereof
TW200607800A (en) 1-aminophthalazine derivatives, preparation thereof and therapeutic application thereof
TW200833690A (en) 3-H-pyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same
TW200714589A (en) Phenylacetamides suitable as protein kinase inhibitors
UA101819C2 (en) Herbicidal 1h-2-thia-1,5,8-triazanaphthalene-2,2-dioxides
EA201200669A1 (ru) ПИРИДОПИРИМИДИНОНОВЫЕ ИНГИБИТОРЫ PI3Kα
AR061838A1 (es) Moduladores de propiedades farmacocineticas de terapeuticos
CY1113676T1 (el) Υποκατεστημενο βητα-φαινυλο-αλφα-υδροξυ προπιονικο οξυ, μεθοδος συνθεσης και χρηση του
SE0401762D0 (sv) Novel compounds
DE602007001463D1 (de) Pyrimidin-, chinazolin-, pteridin- und triazinderivate
TW200621721A (en) Methods of preparing indazole compounds
JO2682B1 (en) Derivatives of alkynil-8.1-naphthayridone, preparations thereof and therapeutic use thereof
PE20091649A1 (es) Derivados de pirrolidinilo
EA200700901A1 (ru) Производные 2-амидо-4-фенилтиазола, их получение и применение в терапии
EA201100696A1 (ru) 1-(арилсульфонил)-4-(пиперазин-1-ил)-1h-бензимидазолы в качестве лигандов 5-гидрокситриптамина-6
EA201070281A1 (ru) Производные индол-2-она, двузамещенные в положении 3, их получение и их применение в терапии
NO20090312L (no) Quinolinonderivater og deres farmasoytiske sammensetninger
UY29036A1 (es) Derivados de oxopiperidina, su preparacion y su aplicacion en terapeutica
WO2008003855A3 (fr) Utilisation de 2-benzoyl-imidazopyridines en thérapeutique
MX2007007027A (es) Derivados piperazinilpiridina como agentes anti-obesidad.
JO2774B1 (en) Derivatives (brprazinil bridges) 1-1 new canon and their use as p75 inhibitors